July 10, 2017 / 5:27 PM / 12 days ago

BRIEF-uniQure announces updated, long-term clinical data from ongoing Phase I/II Trial of AMT-060

1 Min Read

July 10 (Reuters) - uniQure NV:

* uniQure announces updated, long-term clinical data from ongoing phase I/II trial of AMT-060 in patients with severe Hemophilia B

* No activation of T-Cell responses or loss of fix activity in any patient up to 18 months

* ‍AAV5-based AMT-060 remains safe and well-tolerated with up to a year and a half of follow-up​

* Second-dose cohort demonstrates dose response up to one year, with 84 percent reduction in spontaneous bleeds

* All but one patient in study across both cohorts required chronic infusions of prophylactic fix therapy at time of enrollment

* No patients across either cohort developed inhibitory antibodies against FIX, or demonstrated sustained AAV5 capsid-specific T-cell activation Source text for Eikon: Further company coverage: (Reporting by Indranil Sarkar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below